• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Genentech

Genentech

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. FDA Grants Priority Review for Genentech ’s OCREVUS™ (ocrelizumab) Biologics License Application

    FDA Grants Priority Review for Genentech ’s OCREVUS™ (ocrelizumab) Biologics License Application

  2. LabCorp Announces Launch of New Companion Diagnostic for Non-Small Cell Lung Cancer

    LabCorp Announces Launch of New Companion Diagnostic for Non-Small Cell Lung Cancer

  3. Phase III Study Shows Genentech ’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

    Phase III Study Shows Genentech ’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)

  4. Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

    Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting

  5. Genentech ’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer

    Genentech ’s Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer

  6. UPDATE: Venture capital legend Tom Perkins dies at 84

    UPDATE: Venture capital legend Tom Perkins dies at 84

  7. Thomas Perkins, Venture Capitalist Legend, Dies

    Thomas Perkins, Venture Capitalist Legend, Dies

  8. Venture capital legend Tom Perkins dies at 84

    Venture capital legend Tom Perkins dies at 84

  9. Vascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results

    Vascular Biogenics stock up 34% in pre-market trade after positive cancer drug trial results

  10. Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost

    Combination Drug Therapies for Cancer Show Promise at Higher Potential Cost

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.